Drug Profile


Latest Information Update: 03 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rega Institute for Medical Research
  • Class Diagnostic agents; Monoclonal antibodies
  • Mechanism of Action Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Autoimmune disorders; Inflammation

Most Recent Events

  • 02 May 2006 No development reported - Preclinical for Autoimmune disorders (unspecified route)
  • 02 May 2006 No development reported - Preclinical for Inflammation (unspecified route)
  • 17 Mar 2003 Biophage has announced new scientific data for REGA 3G12
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top